At the 2026 BIO International Convention, Zara Asgharpour, Head of External Innovation Integrated Biologics at Lonza, highlighted the transformative potential of artificial intelligence (AI) in biologics workflows. Her insights emphasized the integration of AI across the entire biopharmaceutical value chain, from drug discovery to manufacturing and clinical trials.
Asgharpour articulated that AI is set to revolutionize the operations of Contract Development and Manufacturing Organizations (CDMOs) by enhancing data harmonization and predictive modeling. This integration aims to streamline processes, enabling quicker selection of optimal processes and candidates, ultimately accelerating the path to commercial launch while reducing costs. The digitalization of workflows, she noted, is already yielding significant advantages in drug discovery, particularly in shortening timelines and identifying new applications for existing drugs.
However, Asgharpour also pointed out the challenges faced in embedding AI within the highly regulated healthcare environment. The complexity lies not just in adopting AI technologies but also in managing sensitive data and ensuring regulatory compliance. Establishing a robust data infrastructure is crucial for effective AI application, requiring standardized, harmonized data to achieve reliable outcomes.
Looking ahead, Asgharpour emphasized the importance of collaboration between technology and biotechnology sectors. She noted that partnerships, such as those between tech giants like OpenAI and established biopharma companies, can leverage each industry's strengths. This synergy is essential for overcoming barriers and maximizing the potential of AI in drug development and manufacturing, underscoring a future where both industries learn from each other to enhance innovation.